Health
New study to examine the effects of MS disease-modifying therapy on cognitive fatigue – News-Medical.Net
Kessler Foundation researchers have received support from Genentech, a member of the Roche Group, to conduct an investigator-initiated study on the effects of ocrelizumab…
Kessler Foundation researchers have received support from Genentech, a member of the Roche Group, to conduct an investigator-initiated study on the effects of ocrelizumab (Ocrevus) on cognitive fatigue in individuals with relapsing-remitting multiple sclerosis (MS).
John DeLuca, PhD, senior vice president of Research and Training, is principal investigator for the study titled, “A Biomarker for Cognitive Fatigue in MS using Functional Imaging”. The study team includes Glenn Wylie, DPhil, director…
-
General16 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News19 hours agoSanta drops in for carols
-
General22 hours agoCritically endangered orchid thrives as NSW Mid North Coast cemetery provides habitat refuge
-
Business20 hours agoHow much upside does Macquarie predict for Sonic Healthcare shares?
